RUNX2 and neoplasm: Despite some correlation with pathological grade, clinical stage and tumor size, as well as expression of molecular markers including vascular endothelial growth factor (VEGF) [22,23], matrix metalloproteinase type-9 (MMP-9) [24], p63 [25,26], epidermal growth factor receptor (EGFR) [27], human telomerase reverse transcriptase (hTERT) [28], runt-related transcription factor 2 (RUNX2) [29] and increased proliferation [30], recurrence of GCTB is difficult to predict.